IND approved by US FDA, Start clinical phase 1 early this month
Next generation pneumococcal vaccine global market valued at 5 trillion won

The ‘Next Generation Pneumococcal Vaccine’ from domestic technology starts clinical trials in USA.

SK bioscience (CEO Ahn-Jae-Yong) announced on 12th that its next-generation pneumococcal vaccine, which is being jointly developed with Sanofi Pasteur (President David Loew), has passed the US Food and Drug Administration (FDA)’s investigational new drug application (IND) and entered phase 1 clinical trials earlier this month.

SK chemical, a parent company of SK bioscience, concluded a joint development and sales contract in 2014 with the next-generation pneumococcal vaccine with the aim of advancing into the global market with Sanofi Pasteur, a global vaccine specialist.

Description: SK bioscience vaccine factory can produce most vaccines developed in Korea such as the next generation pneumococcal vaccine, Andong L HOUSE

Under the existing agreement, Sanofi Pasteur will cooperate with SK bioscience to develop the entire pneumococcal vaccine development process, including licensing and marketing.

According to Datamonitor Healthcare, a global market research firm, the pneumococcal vaccine market was estimated to reach about 5.2 trillion KRW in 2016 in the US, Japan, and five major EU countries. The market is expected to grow to about 7.1 trillion won by 2025. (Source: Datamonitor Healthcare, Oct. 3, 2017.)

Ahn Jae-yong, president of SK bioscience, said, “The goal of creating a premium vaccine that leads the global market with next-generation innovative technology is gradually coming to reality.” He emphasized, “We will continue to promote human health through innovative vaccine technology.”

SK bioscience is a vaccine company that was established last July by SK chemicals. The company developed the world’s first tetravalent cell culture flu vaccine ‘SKY CellFlu 4’, and world‘s second shingles vaccine ‘SKY Zoster inj’, and Korea’s second developed varicella vaccine ‘SKY Varicella inj.’